Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 10/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705558 | 1.00 | LSS (0.56) | LSS | |
| SCHEMBL11845594 | 0.90 | LSS (0.45) | LSS | |
| SCHEMBL11845599 | 0.90 | LSS (0.45) | LSS | |
| SCHEMBL1704748 | 0.86 | LSS (0.58) | LSS | |
| SCHEMBL119016 | 0.86 | LSS (0.58) | LSS | |
| SCHEMBL4420765 | 0.86 | LSS (0.58) | LSS | |
| SCHEMBL11848290 | 0.83 | LSS (0.36) | LSS | |
| SCHEMBL11847465 | 0.83 | LSS (0.36) | LSS | |
| SCHEMBL8439651 | 0.81 | LSS (0.63) | LSS | |
| SCHEMBL6319655 | 0.81 | LSS (0.63) | LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060035873-A1 | Methods for inducing apolipoprotein e secretion | ILEX PRODUCTS, INC. | 2006-02-16 | — | — | US | claimed |
| EP-1019059-A4 | USE OF FXR, PPARalpha AND LXRalpha ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION | UNIV CALIFORNIA (US) | 2004-01-14 | — | — | EP | claimed |
| EP-1313483-A2 | METHODS FOR INDUCING APOLIPOPROTEIN E SECRETION | SYMPHAR S.A. (CH) | 2003-05-28 | — | — | EP | claimed |
| WO-2002011708-A2 | METHODS FOR INDUCING APOLIPOPROTEIN E SECRETION | SYMPHAR S.A. (CH) | 2002-02-14 | — | — | WO | claimed |
| JP-2001509165-A | — | — | 2001-07-10 | — | — | JP | claimed |
| US-6187814-B1 | BY TOPICALLY AN FARNESOID X-ACTIVATED RECEPTOR (FXR) ACTIVATOR SELECTED FROM FARNESAL, ALKYL FARNESYL ETHER, ALKYL FARNESOATE, AND 7-METHYL-9-(3,3-DIMETHYLOXIRANYL)-3-METHYL-2,6-NONADIENOIC ACID, ALKYL ESTER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-02-13 | — | — | US | claimed |
| WO-2000049992-A2 | USE OF FXR, PPARα AND LXRα ACTIVATORS TO TREAT ACNE/ACNEIFORM CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-31 | — | — | WO | claimed |
| EP-1019059-A1 | USE OF FXR, PPARalpha AND LXRalpha ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-19 | — | — | EP | claimed |
| WO-1998032444-A1 | USE OF FXR, PPARα AND LXRα ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-07-30 | — | — | WO | claimed |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008039829-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1885694-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | Microbia, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1879860-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | Microbia Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1877067-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-6184215-B1 | TOPICALLY APPLYING TO SKIN A HYDROXYCHOLESTEROL TO ACTIVATE LIVER-BASED X-ACTIVATED RECEPTOR ALPHA (LXRA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-02-06 | — | — | US | disclosed |
| WO-2000049992-A2 | USE OF FXR, PPARα AND LXRα ACTIVATORS TO TREAT ACNE/ACNEIFORM CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-1019059-A1 | USE OF FXR, PPARalpha AND LXRalpha ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-19 | — | — | EP | disclosed |
| US-6071955-A | TREATING TERRESTRIAL MAMMALIAN SUBJECT SUFFERING FROM A CONDITIONS OF ACNE AND ACNEIFORM CONDITIONS BY ADMINISTERING 7-METHYL-9-(3,3-DIMETHYLOXIRANYL)-3-METHYL-2,6-NONADIENOIC ACID METHYL ESTER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-06-06 | — | — | US | disclosed |
| US-6060515-A | TOPICALLY APPLYING TO MAMMALIAN SKIN OR MUCOUS MEMBRANE A BARRIER DEVELOPMENT ENHANCING AMOUNT OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPARA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |
| WO-1998032444-A1 | USE OF FXR, PPARα AND LXRα ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | CYP46A1, CYP7A1, UGT1A1 | LSS 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.